Authors:
AP Greystoke, DI Jodrell, M Cheung, I Rivans, MJ Mackean
Journal name: 
Eur J Cancer Care (Engl)
Citation info: 
19(1):80-90
Abstract: 
The introduction, 30 years ago, of the co-administration of appropriate hydration and ensuring a diuresis occurs during the administration of cisplatin was important in its development, allowing clinically significant doses to be given with acceptable rates of toxicity. The clinical usage of cisplatin has increased and hydration protocols have been amended to increase patient comfort and reduce resource utilization. We suspected that this had led to unnecessary variations in practice both in clinical trials and subsequently in the clinic. Therefore, we reviewed practice in the Edinburgh Cancer Centre and discovered that 25 different hydration protocols were in use, with wide variation in dilution of cisplatin, total fluid administered, use of electrolyte (potassium and magnesium) supplementation and diuretics. These differences are a reflection of adoption of variations in hydration regimes published in pivotal clinical trials. A review of the available evidence relating to cisplatin associated hydration regimens was performed and recommendations will be made for the future design of evidence-based protocols.
DOI: 
http://doi.org/10.1111/j.1365-2354.2007.00908.x
Research group: 
Jodrell Group
E-pub date: 
01 Jan 2010